Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
The consensus price target hints at a 25.7% upside potential for Repligen (RGEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Curtis Ellergodt Rothschild Investment LLC | 466 | $82,861.39 | $74,299.04 | -$8,562.35 | -10.33% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 18,056 | $2.46M | $2.96M | $495,818.22 | 20.13% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 100 | $16,386 | $16,390 | $4 | 0.02% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 12 | $1,654.66 | $1,977.24 | $322.58 | 19.5% |
Wallace Weitz Weitz Investment Management Inc. | 40,800 | $5.09M | $6.72M | $1.63M | 32.02% |
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RW Robert Wasserman Benchmark | 116.86 | $16,340.34 | $16,984.23 | $643.89 | 3.94% |
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Olivier Loeillot CEO | NASDAQ (NGS) Exchange | 759916109 CUSIP |
| US Country | 2,000 Employees | - Last Dividend | - Last Split | 26 Mar 1990 IPO Date |
Repligen Corporation is an innovative force in the biotechnological industry, primarily focusing on the development and commercialization of bioprocessing technologies and systems that play a crucial role in biological drug manufacturing. With a global reach that extends across North America, Europe, the Asia Pacific, and additional international markets, Repligen stands at the forefront of facilitating the production of biological drugs. The company, incorporated in 1981 and based in Waltham, Massachusetts, has established itself as a pivotal contributor to the biopharmaceutical and diagnostics sectors by offering a robust portfolio of products designed to enhance the efficiency and productivity of drug manufacturing processes. Through strategic collaboration agreements, such as with Navigo Proteins GmbH, Repligen continues to expand its technological arsenal, ensuring it remains synonymous with innovation and quality in the bioprocessing industry.